Lupin Q3FY08 Results

Lupin Ltd has announced the following Unaudited results for the quarter ended December 31, 2007:

The Company has posted a net profit of Rs 1702.80 million for the quarter ended December 31, 2007 as compared to Rs 560.30 million for the quarter ended December 31, 2006. Total Income has increased from Rs 5112.00 million for the quarter ended December 31, 2006 to Rs 7470.50 million for the quarter ended December 31, 2007.

The Consolidated results are as follows:

The Group has posted a net profit after minority interest of Rs 1808.60 million for the quarter ended December 31, 2007 as compared to Rs 620.20 million for the quarter ended December 31, 2006. Total Income has increased from Rs 5153.20 million for the quarter ended December 31, 2006 to Rs 8602.30 million for the quarter ended December 31, 2007.

Lupin Q2 results

Lupin Ltd has announced the following Unaudited results for the quarter ended September 30, 2007:

The Company has posted a net profit of Rs 1180.80 million for the quarter ended September 30, 2007 as compared to Rs 583.00 million for the quarter ended September 30, 2006. Total Income has increased from Rs 5120.90 million for the quarter ended September 30, 2006 to Rs 7319.30 million for the quarter ended September 30, 2007.

The Consolidated results are as follows:

The Group has posted a net profit after minority interest of Rs 756.40 million for the quarter ended September 30, 2007 as compared to Rs 518.50 million for the quarter ended September 30, 2006. Total Income has increased from Rs 5056.90 million for the quarter ended September 30, 2006 to Rs 6777.70 million for the quarter ended September 30, 2007.

Lupin Ltd acquires a Japanese company

Lupin Ltd on October 10, 2007 has announced that it has completed arrangements to acquire a significant majority stake in Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa) a leading Japanese generics Company ranked amongst the top 10 Generic Companies.

Kyowa, with sales of ¥ 7.4 Billion for the year ended March 2007, develops, manufactures and markets a range of generics in Japan. Kyowa has a rich product portfolio in the Psychiatry and Neurological therapeutic categories as well as in Cardiovascular, Respiratory & Allergies and Digestive system.

Kyowa has a highly skilled field force. Almost all nationwide wholesalers distribute Kyowa products to hospitals, medical practitioners and Pharmacies making its products widely available and used all over Japan. Kyowa has created a strong brand identity in Japan's generics market through its registered brand "AMEL". Today the "AMEL" brand is recognized and respected as a synonym for quality generics.

Headquartered in Osaka, the business has been built to its current stage by the Promoters, the Sugiura family. The manufacturing facilities are located in Sanda City, Hyogo Prefecture. The Research Centre located in Hyogo Prefecture has strength of about 40 personnel. The development work for products as well as the Regulatory process is handled in-house.

A part of the Company's growth has been fueled by acquisitions. In 1988, the generic business of Boehringer Manheim was acquired which expanded the Psychiatric product specialization. This was followed by the acquisition of the Ospolot business from Bayer, the sales business of Uji Pharmaceutical Co. Ltd. and the sales rights to all prescription drugs of MG Pharma Inc.

Dr. Desh Bandhu Gupta, Chairman, of the Company, said while commenting on the acquisition, "This is a very significant part of our strategy to tap leading global markets and establishes a beachhead in the second largest pharmaceutical market in the world. Kyowa has major strengths in product development, manufacturing and marketing of its products nationwide. Lupin will be able to add significant value through its strengths in R&D and global marketing, leading to major synergies. This acquisition is a signal of our long-term commitment to the Japanese healthcare market."

Lupin

Lupin Ltd, on September 27, 2007 has announced that it has acquired Rubamin Laboratories Ltd (RLL), a part of the Rubamin group. The pharmaceutical business of Rubamin group was operated through its subsidiary RLL, largely engaged in the manufacture of advanced intermediates for APIs under Contract Research And Manufacturing (CRAMS) model.

RLL has over a decade of experience in manufacturing advanced intermediates for APIs. RLL today has capabilities to participate in the value chain from drug development to commercial production of advanced intermediates for APIs. RLL has built a strong customer base and with Company's strengths will be in a better position to support the global pharmaceutical industry.

Dr. Desh Bandhu Gupta, Chairman of the Company said, "We are delighted at this acquisition. It enables us to step up our strategic initiative in the CRAMS segment. We have a proven track record of achieving global position in every therapy that we have entered at intermediate and API level. We are looking forward to replicate our success in this field as well."